Advertisement
New Zealand Markets closed

  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     

  • NZD/USD

    0.6017
    -0.0017 (-0.2769%)
     

  • NZD/EUR

    0.5584
    -0.0010 (-0.18%)
     

  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     

  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     

  • OIL

    79.57
    +0.31 (+0.39%)
     

  • GOLD

    2,375.40
    +35.10 (+1.50%)
     

  • NASDAQ

    18,173.26
    +59.79 (+0.33%)
     

  • FTSE

    8,431.55
    +50.20 (+0.60%)
     

  • Dow Jones

    39,537.93
    +150.17 (+0.38%)
     

  • DAX

    18,761.63
    +75.03 (+0.40%)
     

  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • NZD/JPY

    93.7100
    -0.0580 (-0.06%)
     

Is Eli Lilly Stock a Buy Following This Competitor's Major Win?

Prosper Junior Bakiny, The Motley Fool
·4-min read
Is Eli Lilly Stock a Buy Following This Competitor's Major Win?

Eli Lilly (NYSE: LLY) was already having a great year in the stock market, but on Sept. 28, the company's shares jumped by about 7%. The move happened after biotech giant Biogen and its partner Esai reported positive top-line results from a phase 3 clinical trial for an Alzheimer's disease (AD) therapy candidate, lecanemab. Eli Lilly is working on its own AD treatment, donanemab, and the market counted Biogen's win as Eli Lilly's too.

Continue reading